Print Friendly, PDF & Email

NCT/Study#

NCT03555955 /

CPX351-102

A Phase 1 Trial To Evaluate The Potential Impact Of Renal Impairment On The Pharmacokinetics And Safety Of CPX-351 (Daunorubicin And Cytarabine) Liposome For Injection Treatment In Adult Patients With Hematologic Malignancies

DISEASE GROUP:
Leukemia
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: